PD-1 targeted IL-2Rb/g Agonist ANV600

**Semantic type:** Amino Acid, Peptide, or Protein|Pharmacologic Substance

**Definition:** A bispecific antibody composed of a fusion protein comprised of a monoclonal antibody against the IL-2 receptor subunit alpha (IL2Ra; CD25) binding-site on IL-2 fused to the cytokine IL-2 and an antibody arm against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immunomodulatory and antineoplastic activities. Upon administration of PD-1 targeted IL-2Rb/g agonist ANV600, the anti-PD-1 binding moiety targets and binds to PD-1 on PD-1-postive T-cells within the tumor microenvironment (TME). This allows for the IL-2 moiety to specifically bind to and activate IL-2Rbeta/gamma on PD-1-positive T-cells. The selective IL-2Rbeta (CD122)/gamma (CD132) receptor activation promotes proliferation of neoantigen-specific CD8-positive and PD-1-positive effector T-cells. This enhances a CTL-mediated immune response against tumor cells and decreases tumor cell growth. The alphaIL-2 moiety of the anti-IL-2 antibody/IL-2 fusion protein binds to the IL2Ra binding site on IL-2, thereby preventing the binding of IL-2 to IL2Ra. Signaling through IL2Ra activates CD4-positive immunosuppressive Tregs, which would suppress tumor cell killing.

**Synonyms:** - AN V600 - ANV-600 - ANV600 - Bispecific Antibody ANV600 - Bispecific IL-2Rbeta/gamma Agonist ANV600 - PD-1 targeted Anti-IL-2 Antibody/IL-2 Fusion Protein ANV600 - aIL-2/IL-2 Fusion Protein-Anti-PD-1 Antibody ANV600